Our strategic
drivers

Tom Garthwaite

Patient with Hunter syndrome

We are committed to leading the way in treatments for rare diseases such as Hunter syndrome, with the goal of helping patients like Tom lead better lives. We take inspiration from patients like Tom, continuing to research and develop innovative treatments for diseases that are often unheard of and unrecognized, providing hope for a better tomorrow.

We work together as one to excel across four key strategic drivers:

Joseph Tauber, MD

Tauber Eye Center
Kansas City, MO, US

We make the most of our distinctive mix of businesses to drive continued growth. In 2014 we added our new Ophthalmics business. With the help of specialists such as Dr. Joe Tauber and Dr. Howard Mayer (Shire), we are working on a number of developments in this specialist area, notably our potential treatments for Dry Eye Disease and for the prevention of retinopathy of prematurity (ROP).

Growth

For Shire, growth is both a means and an end. Sustained high growth across all our business units enables us to fuel further R&D and in turn develop innovative new products for patients with unmet needs. Growth drives our revenues and profits. It adds to our momentum. Growth, too, is a great marker of our progress, as we strive to achieve our 10 x 20 target to double our product sales to $10 billion by 2020.

We are on track to file lifitegrast in 2015, and recently received Fast Track designation from the FDA on SHP607

Flemming Ornskov, CEO
  • Product sales
    $5,830m
  • Product sales growth
    23%
  • Double digits growth products
    6
  • Non GAAP cash generation1
    $2,402m

Cindy Hahn

Founder and CEO The Alagille Syndrome Alliance (ALGSA)

With our focus on rare diseases and other speciality conditions we are always looking to build on our existing strengths and extend our expertise to new and complementary areas. Through our acquisition of Lumena, for example, we are in clinical trials with SHP625 for the treatment of Alagille Syndrome, collaborating with patient advocates like Cindy to advance our understanding and capabilities and help patients in need.

Innovation

Innovation is the lifeblood of our current and future success. We seek to focus our innovation across areas with high medical need. To this end, we aim to expand our rare disease expertise and offerings through research and partnerships, and to extend our existing portfolio of products to new indications and therapeutic areas.

pie-chart
60

2014 Number of programs
in pipeline

as at December 31, 2014
  • Pre-clinical 33
  • Phase 1 7
  • Phase 2 11
  • Phase 3 7
  • Registration 2
$840m
2014 Investment in
Non GAAP R&D1

Our new International Operational HQ

Zug, Switzerland

By maximizing efficiency across Shire we free up greater resources to focus on researching, developing and bringing to market much needed treatments for patients. One example of improved efficiency is the consolidation of our global hubs into our US Operational HQ in Lexington, MA and an International Operational HQ in Zug, Switzerland.

Efficiency

Our ongoing focus on efficiency enables us to reinvest in continued growth. The leaner and more agile we are as an organization, the more able we are to fuel and fulfil our purpose to enable people with life altering conditions to lead better lives.

Ongoing efficiency program

  • Integrated R&D under a single team
  • Created a geographic footprint with two major hubs
  • Streamlined other corporate functions and internal processes
  • Divesting non-core assets (e.g. DERMAGRAFT)

Significant margin improvement $ million; percent of product sales1, 2

2014: 44% EBITDA, 28% SG and A, 14% R and D, 14% COGS, 5830 total. 2013: 38% EBITDA, 30% SG and A, 19% R and D, 13% COGS, 4758 total.

1This is a Non GAAP financial measure. For reconciliation to US GAAP please see page 166 of the Annual Report.
2Results from continuing operations including ViroPharma Inc. and excluding DERMAGRAFT.

Members of the Rare
Disease Business Unit

Zug, Switzerland

From our new International Operational Headquarters in Zug, to our sales forces around the world, we work together as a close-knit, resilient team dedicated to achieving high performance. Our people are highly loyal and committed. Throughout Shire, we strive to create a great place to work, where people can perform and progress to their full potential. Our shared purpose is to help people with life-altering conditions lead better lives.

People

Our people are at the heart of our journey to become a leading biotech delivering innovative global medicines to patients with rare diseases and other specialty conditions. We focus on attracting and retaining great people and giving them an environment where they are encouraged to excel.

Ongoing efficiency program

  • Foster and reward a high-performance culture
  • Attract, develop and retain the best talent
  • Live our values

Overall gender breakdown

as at December 31, 2014

2014: 51% male, 49% female. 2013: 51% male, 49% female
  • Male
  • Female

2014 employment by region

as at December 31, 2014

2014: 51% male, 49% female. 2013: 51% male, 49% female